Importantly, as DEPTOR is strongly expressed in some cancers, including multiple myeloma, clinical suppression of DEPTOR expression or activity, or its downstream signaling pathway, may achieve the best combination for prevention of cisplatin-induced injury and cisplatin antitumor efficacy. The gene discussed is DEPTOR; the disease is AL amyloidosis.